Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES AGM RESULTS AND PROVIDES CORPORATE UPDATES

Defence Therapeutics Inc. shareholders approved all matters presented at the company's annual general meeting of the shareholders held today, as detailed in an attached table.

Grant of options

Defence has granted a total of 800,000 stock options to certain directors, officers and employees pursuant to the company's omnibus incentive plan. The options, subject to the terms of the plan, are exercisable at a price of 82 cents per Class A common share of the company for a period of 10 years.

Warrant terms amendments

Defence also announces an amendment to the terms of a total of 967,000 common share purchase warrants originally issued as part of a private placement that closed on Jan. 30, 2024, and March 22, 2024, respectively. The expiry date will be extended by 12 months and the exercise price will be repriced at $1 per common share, as detailed in an attached table.

All other terms of the warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finders' warrants are not eligible for amendment.

Marketing service engagement

On Sept. 30, 2025, Defence entered into an online marketing agreement for a term of two months, which commenced on approximately Nov. 3, 2025, with i2i Marketing Group LLC for total cash consideration of $300,000 (U.S.), with $50,000 paid on the date of the agreement and the remaining to be paid upon the completion of conditions set for in the agreement. Thereafter, the agreement continues on a month-to-month basis with supplemental expenditures agreed to by the parties for the services being rendered. Pursuant to the terms of the agreement, i2i will provide certain marketing and distribution services, including content creation management, author sourcing, project management and media distribution. i2i is a private company headquartered in Key West, Fla., (e-mail: contact@i2illc.com; address: 1107 Key Plaza, No. 222, Key West, Fla., 33040; phone: 240-7315-4665), dedicated to providing marketing services. The company will not issue any securities to i2i as compensation. i2i and its principals are arm's length from the company and do not have any interest, direct or indirect, in the company or its securities, nor do they have any right to acquire such an interest.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company working on engineering the next-generation ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of biologics in their intact form to target cells. As a result, efficacy and potency can be enhanced for biologics enabling expanded patient access and market opportunities.

We seek Safe Harbor.